Literature DB >> 22223135

Attitudes and preferences toward the provision of medication abortion in an urban academic internal medicine practice.

Cameron Page1, Sarah Stumbar, Marji Gold.   

Abstract

BACKGROUND: Mifepristone offers internal medicine doctors the opportunity to greatly expand access to abortion for their patients. Almost 70% of pregnancy terminations, however, still occur in specialized clinics. No studies have examined the preferences of Internal Medicine patients specifically.
OBJECTIVE: Determine whether patient preference is a reason for the limited uptake of medication abortion among internal medicine physicians. PARTICIPANTS: Women aged 18-45 recruited from the waiting room in an urban academic internal medicine clinic. MEASURES: A semi-structured questionnaire was used to determine risk of unintended pregnancy and attitudes toward abortion. Support for provision of medication abortion in the internal medicine clinic was assessed with a yes/no question, followed by the open-ended question, "Why do you think this clinic should or should not offer medication abortion?" Subjects were asked whether it was very important, somewhat important, or not important for the internal medicine clinic to provide medication abortion. KEY
RESULTS: Of 102 women who met inclusion criteria, 90 completed the survey, yielding a response rate of 88%. Twenty-two percent were at risk of unintended pregnancy. 46.7% had had at least one lifetime abortion. Among those who would consider having an abortion, 67.7% responded yes to the question, "Do you think this clinic should offer medication abortions?" and 83.9% stated that it was "very important" or "somewhat important" to offer this service. Of women open to having an abortion, 87.1% stated that they would be interested in receiving a medication abortion from their primary care doctor.
CONCLUSIONS: A clinically significant proportion of women in this urban internal medicine clinic were at risk of unintended pregnancy. Among those open to having an abortion, a wide majority would consider receiving it from their internal medicine doctor. The provision of medication abortion by internal medicine physicians has the potential to greatly expand abortion access for women.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22223135      PMCID: PMC3358384          DOI: 10.1007/s11606-011-1956-6

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  16 in total

1.  Provider practice models for and costs of delivering medication abortion -- evidence from 11 US abortion care settings.

Authors:  Aimee Afable-Munsuz; Heather Gould; Felicia Stewart; Kathryn A Phillips; Stephanie L Van Bebber; Charlie Moore
Journal:  Contraception       Date:  2006-11-14       Impact factor: 3.375

2.  Determinants of physician unwillingness to offer medical abortion using mifepristone.

Authors:  Michelle D Seelig; Lillian Gelberg; Paula Tavrow; Martin Lee; Lisa V Rubenstein
Journal:  Womens Health Issues       Date:  2006 Jan-Feb

3.  Early pregnancy termination with mifepristone and misoprostol in the United States.

Authors:  I M Spitz; C W Bardin; L Benton; A Robbins
Journal:  N Engl J Med       Date:  1998-04-30       Impact factor: 91.245

4.  Abortion and the public opinion polls. 1. Morality and legality.

Authors:  S K Henshaw; G Martire
Journal:  Fam Plann Perspect       Date:  1982 Mar-Apr

5.  Willing and able? Provision of medication for abortion by future internists.

Authors:  Eleanor Bimla Schwarz; Anne Luetkemeyer; Diana Greene Foster; Tracy A Weitz; Deborah Lindes; Felicia H Stewart
Journal:  Womens Health Issues       Date:  2005 Jan-Feb

6.  Predictors of acceptability of medication abortion.

Authors:  Stephanie B Teal; Angela Dempsey-Fanning; Carolyn Westhoff
Journal:  Contraception       Date:  2007-01-16       Impact factor: 3.375

7.  The effect of patient-centered contraceptive counseling in women who undergo a voluntary termination of pregnancy.

Authors:  Maria Patrizia Nobili; Sabrina Piergrossi; Valentina Brusati; Egidio Aldo Moja
Journal:  Patient Educ Couns       Date:  2006-11-27

8.  Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial.

Authors:  E A Schaff; S L Fielding; C Westhoff; C Ellertson; S H Eisinger; L S Stadalius; L Fuller
Journal:  JAMA       Date:  2000-10-18       Impact factor: 56.272

9.  Abortion patients in 1994-1995: characteristics and contraceptive use.

Authors:  S K Henshaw; K Kost
Journal:  Fam Plann Perspect       Date:  1996 Jul-Aug

10.  Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol.

Authors:  R Peyron; E Aubény; V Targosz; L Silvestre; M Renault; F Elkik; P Leclerc; A Ulmann; E E Baulieu
Journal:  N Engl J Med       Date:  1993-05-27       Impact factor: 91.245

View more
  6 in total

1.  Reproductive health services in internal medicine.

Authors:  Nathan K Boddie
Journal:  J Gen Intern Med       Date:  2012-09       Impact factor: 5.128

2.  Exploring Medication Abortion Training in an Internal Medicine Primary Care Residency Program.

Authors:  Robyn Winsor; Marji Gold; Zoey Thill
Journal:  J Gen Intern Med       Date:  2021-03-29       Impact factor: 5.128

3.  The Future of Medical Abortion Care: an Internal Medicine Obligation.

Authors:  Olgert Bardhi; Patrick E Rizk
Journal:  J Gen Intern Med       Date:  2022-09-29       Impact factor: 6.473

Review 4.  Medication to Manage Abortion and Miscarriage.

Authors:  Jessica Beaman; Christine Prifti; Eleanor Bimla Schwarz; Mindy Sobota
Journal:  J Gen Intern Med       Date:  2020-05-14       Impact factor: 5.128

5.  Perspectives of internal medicine physicians regarding medication abortion provision in the primary care setting.

Authors:  Tierney Wolgemuth; Colleen Judge-Golden; Katherine Lane; Jamie Stern; Sonya Borrero
Journal:  Contraception       Date:  2021-04-22       Impact factor: 3.375

6.  Making Medication Abortion a Part of Internal Medicine.

Authors:  Xanthia A Tucker
Journal:  J Gen Intern Med       Date:  2021-05-07       Impact factor: 5.128

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.